CGRP (Calcitonin Gene-Related Peptide)

1. Overview

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide that holds the distinction of being the most potent endogenous vasodilator known in humans [2][3]. Discovered in 1982 by Amara and colleagues through the identification of alternative RNA splicing of the calcitonin gene, CGRP represented the first demonstration that tissue-specific alternative splicing could generate functionally distinct peptide hormones from a single gene [1]. This neuropeptide has since become one of the most clinically significant molecules in modern neurology, with seven FDA-approved drugs targeting its pathway for migraine treatment.

CGRP exists in two isoforms: alpha-CGRP (α-CGRP) and beta-CGRP (β-CGRP). α-CGRP is produced by alternative splicing of the CALCA gene (calcitonin gene) on chromosome 11p15.2. In thyroid C cells, CALCA mRNA is spliced to include exon 4, producing calcitonin, whereas in sensory neurons the transcript is spliced to include exons 5 and 6 instead, producing α-CGRP [1][4]. β-CGRP is encoded by a separate gene, CALCB, also located on chromosome 11. The two isoforms share greater than 90% sequence homology in humans, differing at only three amino acid positions (3, 22, and 25) [4][16].

Human α-CGRP has a molecular weight of approximately 3,789 Da (molecular formula C167H269N51O55S3). Both isoforms share critical structural features: a disulfide bridge between Cys2 and Cys7 that forms a ring structure essential for receptor activation, and a C-terminal amidated phenylalanine residue required for biological activity [4]. The N-terminal ring structure (residues 1–7) is required for receptor activation, the middle region (residues 8–18) forms an alpha-helix that serves as a spacer, and the C-terminal segment (residues 19–37) is critical for receptor binding [16][27].

CGRP is predominantly expressed in small- and medium-diameter sensory neurons of the dorsal root ganglia and trigeminal ganglia, where it is one of the most abundant neuropeptides. It is also found in the central nervous system (hypothalamus, cerebellum, brainstem) and in perivascular nerve fibers innervating cerebral, meningeal, coronary, and peripheral blood vessels [4][17]. CGRP signals through a unique heterodimeric receptor complex consisting of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1), coupled with the intracellular receptor component protein (RCP) [4][27].

Molecular Weight

~3,789 Da (α-CGRP)

Sequence Length

37 amino acids

Isoforms

α-CGRP (CALCA gene, chr 11) and β-CGRP (CALCB gene, chr 11)

Molecular Formula

C167H269N51O55S3 (human α-CGRP)

Key Structural Features

Disulfide bridge (Cys2–Cys7); C-terminal amidated phenylalanine

Primary Receptor

CLR/RAMP1 heterodimer (calcitonin receptor-like receptor + RAMP1)

Discovery

Amara et al., 1982 (alternative RNA splicing of calcitonin gene)

FDA-Approved Anti-CGRP Therapies

7 drugs: erenumab, fremanezumab, galcanezumab, eptinezumab, rimegepant, ubrogepant, atogepant

2. Discovery and Historical Context

The discovery of CGRP emerged from groundbreaking molecular biology research at the University of California, San Diego. In 1982, Michael Rosenfeld, Susan Amara, and Ronald Evans demonstrated that the calcitonin gene undergoes tissue-specific alternative RNA processing: in thyroid C cells, the primary transcript is spliced to produce calcitonin mRNA, while in neurons, the same gene produces a distinct mRNA encoding a previously unknown 37-amino-acid peptide they named calcitonin gene-related peptide [1]. This was the first example of alternative RNA splicing generating different peptide hormones from a single gene, a finding that had profound implications for understanding gene regulation and neuropeptide biology.

Shortly after its discovery, two landmark studies in Nature established the remarkable vasodilatory potency of CGRP. In 1985, Brain and colleagues demonstrated that CGRP is a potent vasodilator in multiple vascular beds [2]. By 1986, Fisher and colleagues confirmed CGRP as "the most potent vasodilator known," with activity exceeding that of prostaglandins and all other characterized endogenous vasodilators — active at femtomole concentrations when injected intradermally [3].

The connection between CGRP and migraine emerged in 1990, when Peter Goadsby and Lars Edvinsson published a pivotal study demonstrating that CGRP levels were significantly elevated in jugular venous blood during migraine attacks [5]. This observation was transformative, as it provided the first direct biochemical evidence linking a specific neuropeptide to migraine pathophysiology. Subsequent studies showed that intravenous infusion of CGRP could trigger migraine-like headaches in susceptible individuals, and that CGRP levels normalized following successful triptan treatment, firmly establishing CGRP as a central mediator of migraine [14][28].

The therapeutic targeting of CGRP began with the development of small-molecule CGRP receptor antagonists (gepants) in the early 2000s. While first-generation gepants such as olcegepant (BIBN4096BS) showed proof of concept in clinical trials, hepatotoxicity concerns halted their development. Second-generation gepants and monoclonal antibodies overcame these challenges, leading to a remarkable decade of FDA approvals beginning with erenumab in May 2018 [14].

3. Mechanism of Action

The CGRP Receptor Complex: CLR/RAMP1

The CGRP receptor is a heterodimeric complex with a unique architecture among G protein-coupled receptors (GPCRs). It consists of three components: (1) the calcitonin receptor-like receptor (CLR), a class B GPCR; (2) receptor activity-modifying protein 1 (RAMP1), a single-transmembrane-domain accessory protein; and (3) receptor component protein (RCP), an intracellular peripheral membrane protein [4][27].

RAMP1 is essential for CGRP receptor function — without it, CLR cannot reach the cell surface and cannot bind CGRP. RAMP1 serves dual roles: it chaperones CLR from the endoplasmic reticulum to the plasma membrane, and it contributes directly to the ligand-binding pocket that confers specificity for CGRP over other calcitonin family peptides. Notably, when CLR associates with RAMP2 instead of RAMP1, it forms the adrenomedullin-1 receptor, and when paired with RAMP3, it forms the adrenomedullin-2 receptor. This RAMP-dependent receptor switching is a distinctive feature of the calcitonin family receptor system [16][27].

Signal Transduction

Upon CGRP binding, the CLR/RAMP1 complex activates the Gαs subunit, which stimulates adenylyl cyclase and increases intracellular cyclic AMP (cAMP). cAMP activates protein kinase A (PKA), leading to phosphorylation of multiple downstream targets including ATP-sensitive potassium channels (KATP), extracellular signal-regulated kinases (ERK), and the transcription factor cAMP response element-binding protein (CREB) [4]. The intracellular RCP protein links the receptor complex to this Gαs-mediated signaling cascade.

In vascular smooth muscle cells, the CGRP-induced elevation of cAMP and PKA activation produces vasodilation through three convergent mechanisms: (1) reduction of intracellular calcium concentration, (2) decreased binding affinity of myosin light chain kinase (MLCK) for the calcium-calmodulin complex, and (3) opening of KATP channels, which hyperpolarizes the smooth muscle cell membrane. Together, these effects produce robust smooth muscle relaxation and vasodilation [3][4][19].

CGRP can also signal through Gαq in certain cell types, activating phospholipase C and mobilizing intracellular calcium. In endothelial cells, CGRP stimulates endothelial nitric oxide synthase (eNOS) to produce nitric oxide (NO), which diffuses to adjacent smooth muscle cells and provides an additional endothelium-dependent vasodilatory mechanism [4][19].

Vasodilation: The Most Potent Endogenous Vasodilator

CGRP's vasodilatory potency is remarkable. Intradermal injection of CGRP at femtomole doses induces measurable microvascular dilation and increased blood flow in human skin. Systemically, CGRP is 10 to 100 times more potent than other established vasodilators including acetylcholine, substance P, and prostaglandins [2][3]. CGRP-mediated vasodilation is particularly prominent in cerebral, meningeal, coronary, and cutaneous vascular beds — precisely the territories innervated by CGRP-containing sensory neurons.

The vasodilatory effect of CGRP is endothelium-independent in most vascular beds (acting directly on smooth muscle via cAMP/PKA), although an endothelium-dependent component mediated by NO contributes in some vessels. The duration of vasodilation is notably prolonged, lasting several hours after a single exposure, which distinguishes CGRP from short-acting vasodilators [3][4].

The Trigeminovascular System and Migraine

CGRP plays a central role in the trigeminovascular system, the neural-vascular interface considered the primary anatomical substrate for migraine headache. The trigeminal ganglion contains the cell bodies of sensory neurons whose peripheral branches innervate the meningeal blood vessels (dura mater) and whose central branches project to the trigeminal nucleus caudalis (TNC) in the brainstem [17][18].

During a migraine attack, activation of trigeminal sensory neurons triggers the release of CGRP from both peripheral nerve terminals (at meningeal vessels) and central terminals (in the TNC). Peripherally released CGRP causes meningeal vasodilation, plasma protein extravasation, and mast cell degranulation — collectively termed "neurogenic inflammation." This inflammatory cascade further sensitizes nociceptive fibers, lowering the threshold for pain signaling [14][18].

Within the trigeminal ganglion itself, secreted CGRP acts on neighboring neurons and satellite glial cells that express CLR/RAMP1 receptors, creating paracrine signaling loops that amplify and perpetuate the pain signal. CGRP released from neuronal cell bodies stimulates satellite glial cells to release pro-inflammatory mediators, which in turn sensitize adjacent neurons — a mechanism contributing to peripheral sensitization [17][18].

Centrally, CGRP released at the TNC facilitates synaptic transmission and contributes to central sensitization of second-order neurons that project to the thalamus and cortex. CGRP enhances the excitatory effects of substance P and glutamate on nociceptive neurons, amplifying pain signal transmission [15].

Pain Transmission Beyond Migraine

CGRP is synthesized in up to 50% of small- and medium-sized dorsal root ganglion (DRG) neurons and is transported to their central terminals in the spinal cord dorsal horn, where it functions as a neuromodulator of nociceptive processing [15]. In the dorsal horn, CGRP facilitates synaptic plasticity through postsynaptic mechanisms: it potentiates the excitatory effects of substance P and glutamate on dorsal horn projection neurons, contributing to wind-up and central sensitization [15].

A distinct population of CGRP-expressing excitatory interneurons has been identified in lamina III of the spinal dorsal horn. These interneurons, normally suppressed by inhibitory inputs, can become hyperexcitable under pathological conditions and contribute to the development of mechanical allodynia [15]. Additionally, CGRP-responsive neurons in the thalamus have been shown to define a spinothalamic pathway for affective (emotional) pain processing, suggesting CGRP contributes to the suffering dimension of pain [15].

4. Researched Applications

Migraine Prevention — Monoclonal Antibodies

Evidence level: Strong (four FDA-approved drugs)

The development of anti-CGRP monoclonal antibodies represents one of the most successful examples of targeted neuropeptide therapy in clinical medicine. Four monoclonal antibodies are FDA-approved for migraine prevention, targeting either the CGRP ligand or its receptor:

Erenumab (Aimovig) — FDA-approved May 2018. Erenumab is unique among the anti-CGRP monoclonal antibodies as the only one that targets the CGRP receptor (CLR/RAMP1) rather than the CGRP peptide itself. It is a fully human IgG2 monoclonal antibody. In the pivotal STRIVE trial, erenumab 70 mg and 140 mg monthly subcutaneous injections reduced monthly migraine days by 3.2 and 3.7 days respectively, compared to 1.8 days for placebo. The 50% responder rates were 43.3% and 50.0% vs. 26.6% for placebo [6].

Fremanezumab (Ajovy) — FDA-approved September 2018. A fully humanized IgG2Δa monoclonal antibody that binds the CGRP ligand. In the HALO chronic migraine trial, both monthly (225 mg) and quarterly (675 mg) dosing reduced monthly headache days of at least moderate severity by 4.6 and 4.3 days respectively, compared to 2.5 days for placebo [7]. The flexible dosing schedule (monthly or quarterly) distinguishes fremanezumab from the other subcutaneous options.

Galcanezumab (Emgality) — FDA-approved September 2018 for migraine; June 2019 for episodic cluster headache. A humanized IgG4 monoclonal antibody targeting the CGRP ligand. In the EVOLVE-1 trial, galcanezumab 120 mg and 240 mg reduced monthly migraine days by 4.7 and 4.6 days respectively vs. 2.8 for placebo [8]. Galcanezumab is the only anti-CGRP monoclonal antibody also approved for episodic cluster headache prevention, at a higher dose of 300 mg monthly.

Eptinezumab (Vyepti) — FDA-approved February 2020. A humanized IgG1 monoclonal antibody targeting the CGRP ligand, and the only anti-CGRP antibody administered intravenously. In the PROMISE-1 trial, eptinezumab 100 mg and 300 mg administered quarterly by IV infusion significantly reduced monthly migraine days, with the notable distinction of demonstrating efficacy onset as early as day 1 after infusion [9].

In patients who had failed prior preventive treatments, anti-CGRP antibodies showed consistent efficacy: 50% responder rates were 30% for erenumab 140 mg (LIBERTY trial), 34% for fremanezumab (FOCUS trial), 38% for galcanezumab 120 mg (CONQUER trial), and 42–49% for eptinezumab 100–300 mg (DELIVER trial) [6][7][8][9].

Acute Migraine Treatment and Prevention — Gepants

Evidence level: Strong (three FDA-approved drugs)

The gepants are small-molecule CGRP receptor antagonists that represent a distinct pharmacological approach from the monoclonal antibodies. Unlike the antibodies, gepants are orally bioavailable, have shorter half-lives (hours rather than weeks), and can be used for both acute and preventive treatment.

Ubrogepant (Ubrelvy) — FDA-approved December 2019 for acute migraine. In the pooled ACHIEVE I and ACHIEVE II trial analyses, ubrogepant 50 mg achieved 2-hour pain freedom in 20.5% of patients vs. 13.0% for placebo, and freedom from the most bothersome symptom in 38.7% vs. 27.6%. The 100 mg dose showed 2-hour pain freedom of 21.8%. The safety profile was notably benign, with adverse event rates comparable to placebo and no evidence of vasoconstriction or hepatotoxicity [10].

Rimegepant (Nurtec ODT) — FDA-approved February 2020 for acute migraine; May 2021 for preventive treatment. Rimegepant is the only gepant approved for both acute and preventive indications. For acute treatment, 75 mg achieved 2-hour pain freedom in approximately 20–21% of patients vs. 11–12% for placebo. For prevention, rimegepant 75 mg every other day reduced monthly migraine days by 4.3 vs. 3.5 for placebo over 12 weeks [11][12]. Its dual utility allows patients to use a single medication for both purposes.

Atogepant (Qulipta) — FDA-approved September 2021 for migraine prevention. In the ADVANCE trial, atogepant 10 mg, 30 mg, and 60 mg daily all significantly reduced monthly migraine days over 12 weeks (reductions of 3.7, 3.9, and 4.2 days vs. 2.5 for placebo). The 60 mg once-daily dose is recommended for chronic migraine [13]. Atogepant is the only gepant approved exclusively for prevention.

Across the gepant class, safety profiles have been reassuring, with mild adverse events (nausea, fatigue) and no evidence of vasoconstriction, medication-overuse headache, or hepatotoxicity in contemporary formulations. The number needed to treat (NNT) for 2-hour pain freedom is approximately 9 for rimegepant, 11 for zavegepant (a nasal spray gepant), and 12 for ubrogepant [10][11][13].

Cardiovascular Protection and Heart Failure

Evidence level: Moderate (preclinical and translational studies)

CGRP is a crucial regulator of cardiovascular homeostasis with potent vasodilatory, cardioprotective, anti-inflammatory, and antifibrotic properties. CGRP-containing sensory nerves innervate cardiac tissue and the vasculature, where the peptide maintains vascular tone, enhances myocardial perfusion, and counteracts maladaptive neurohormonal activation [4][19].

In heart failure, CGRP's role appears to be stage-dependent. In early heart failure, elevated CGRP levels provide compensatory benefits by reducing afterload, preserving endothelial integrity, and mitigating ventricular remodeling. CGRP has been shown to alleviate multiple aspects of heart failure pathophysiology, including cardiac hypertrophy, reperfusion injury, cardiac inflammation, and apoptosis [4][19]. CGRP protects against cardiovascular dysfunction independently of nitric oxide in vivo, suggesting redundant protective mechanisms [19].

In hypertension research, CGRP acts as a compensatory vasodilator — endogenous CGRP release increases in hypertensive states, and exogenous CGRP administration reduces blood pressure. CGRP-knockout mice develop more severe hypertension and end-organ damage, suggesting the peptide serves as an endogenous brake on pathological blood pressure elevation [4][19].

Raynaud's Phenomenon

Evidence level: Moderate (clinical trials)

The potent vasodilatory capacity of CGRP led to clinical investigation in Raynaud's phenomenon, a condition characterized by episodic vasospasm of digital arteries. In double-blind randomized trials, intravenous CGRP infusion effectively dilated the compromised digital cutaneous vasculature. Blood flow was significantly increased in both hands and fingers, and thermographic results showed significant improvement in hand rewarming up to 3 days after CGRP infusion [21].

In patients with severe secondary Raynaud's phenomenon complicated by digital ulcers, all ulcers healed in four of five CGRP-treated patients compared to no healing in saline-treated controls. CGRP showed prolonged effects compared to prostacyclin in a head-to-head comparison [21].

Importantly, the converse concern also applies: because CGRP blockade could theoretically worsen Raynaud's symptoms, pharmacovigilance studies have examined whether anti-CGRP migraine therapies trigger or exacerbate Raynaud's phenomenon. Disproportionality analyses of the FDA Adverse Event Reporting System have identified a potential safety signal, though recent controlled studies suggest that anti-CGRP monoclonal antibodies are not associated with a significantly increased risk of Raynaud's phenomenon [25].

Wound Healing and Tissue Repair

Evidence level: Moderate (preclinical mechanistic studies)

A 2024 study published in Nature revealed that CGRP from nociceptor sensory neurons plays a critical role in promoting tissue healing. Nociceptor endings grow into injured skin and muscle tissues and signal to immune cells through CGRP during the healing process [22].

CGRP acts via RAMP1 receptors on neutrophils, monocytes, and macrophages to orchestrate a coordinated pro-repair immune response: it inhibits excessive neutrophil and macrophage recruitment toward chemokines found in wounds, triggers neutrophil and macrophage cell death in the presence of proinflammatory cytokines (preventing prolonged inflammation), enhances macrophage efferocytosis (clearance of dead cells), and polarizes macrophages toward a pro-repair phenotype in the presence of anti-inflammatory cytokines [22].

In functional studies, delivery of an engineered CGRP analogue to mice lacking nociceptors and to diabetic mice with peripheral neuropathies accelerated wound closure by approximately 2.5-fold and enhanced muscle regeneration by 1.6-fold [22]. These findings have therapeutic implications for chronic non-healing wounds in patients with diabetes and peripheral neuropathy, conditions in which impaired sensory innervation may directly contribute to poor healing through loss of CGRP signaling.

Cerebral Vasospasm and Subarachnoid Hemorrhage

Evidence level: Emerging (preclinical and early clinical studies)

CGRP depletion from perivascular nerves has been implicated in cerebral vasospasm following subarachnoid hemorrhage (SAH), a devastating complication that is a leading cause of death and disability in SAH survivors. CGRP-containing nerve fibers surrounding cerebral arteries are depleted after SAH, and intracisternal administration of CGRP has shown promise in preventing or reversing experimental vasospasm [4][26].

5. Clinical Evidence Summary

6. Molecular Comparisons Within the Calcitonin Peptide Family

CGRP belongs to the calcitonin family of peptides, which includes calcitonin, amylin (IAPP), adrenomedullin, and adrenomedullin 2 (intermedin). All share structural features including an N-terminal disulfide ring and a C-terminal amide, and all signal through class B GPCRs paired with RAMPs [16][27].

| Feature | α-CGRP | β-CGRP | Calcitonin | Amylin | Adrenomedullin | |---|---|---|---|---|---| | Length | 37 aa | 37 aa | 32 aa | 37 aa | 52 aa | | Gene | CALCA (chr 11) | CALCB (chr 11) | CALCA (chr 11) | IAPP (chr 12) | ADM (chr 11) | | Receptor | CLR/RAMP1 | CLR/RAMP1 | CTR | CTR/RAMP1-3 | CLR/RAMP2 | | Key function | Vasodilation, migraine | Vasodilation (GI) | Calcium homeostasis | Glycemic control | Vasodilation, cardioprotection | | Splicing relationship | Alt. splice of CALCA | Separate gene | Primary CALCA product | No relation | No relation |

α-CGRP and β-CGRP differ at only three amino acid positions and share virtually identical pharmacological activity. However, their tissue distribution differs: α-CGRP predominates in sensory neurons (trigeminal and dorsal root ganglia), while β-CGRP is more abundant in the enteric nervous system and motor neurons. Both isoforms bind the CLR/RAMP1 receptor with similar affinity [4][16].

The relationship between CGRP and calcitonin is particularly noteworthy: they are produced from the same gene (CALCA) through mutually exclusive alternative splicing events. The tissue-specific splicing factors that direct exon 4 inclusion (calcitonin) in thyroid C cells versus exon 5/6 inclusion (CGRP) in neurons represent a fundamental example of how a single gene can serve entirely different physiological functions depending on cellular context [1][4].

7. Safety Considerations

Cardiovascular Concerns

The most frequently discussed safety concern with anti-CGRP therapies is the theoretical cardiovascular risk of blocking a potent endogenous vasodilator and cardioprotective peptide. Because CGRP serves protective functions in the cardiovascular system — including vasodilation, cardioprotection during ischemia-reperfusion, and counterregulation of hypertension — long-term blockade raised concerns about increased risk of hypertension, stroke, myocardial infarction, and impaired response to cardiac ischemia [20][25].

Reassuringly, clinical trial data and post-marketing surveillance through multiple years of use have not demonstrated increased cardiovascular event rates in migraine patients treated with anti-CGRP therapies. A study specifically examining cardiovascular safety of anti-CGRP monoclonal antibodies in older adults and adults with disability found no increased risk of composite cardiovascular disease events, hypertensive crisis, peripheral revascularization, or Raynaud's phenomenon [25]. However, patients with established cardiovascular disease were largely excluded from pivotal trials, and long-term surveillance in higher-risk populations remains important [20][25].

Constipation

Constipation has emerged as the most clinically significant gastrointestinal side effect of anti-CGRP therapies, particularly with monoclonal antibodies. While clinical trials reported relatively low rates, post-approval real-world surveys reveal constipation may affect more than 50% of patients treated with erenumab, fremanezumab, or galcanezumab [24].

The mechanism is well-characterized: CGRP has motor-stimulating and prosecretory functions in the intestine, promoting peristalsis and fluid secretion. Blockade of CGRP signaling reduces intestinal motility and secretion, leading to constipation. This effect is most pronounced with erenumab (which blocks the receptor at all tissue sites) and with the monoclonal antibodies (which have sustained CGRP blockade over weeks due to long half-lives). Gepants, with their shorter half-lives and intermittent dosing, appear to cause less constipation [24].

Other Safety Considerations

Additional adverse effects reported with anti-CGRP monoclonal antibodies include injection site reactions (pain, erythema, pruritus), fatigue, and alopecia. Anaphylactic reactions have been reported rarely with eptinezumab and galcanezumab [25]. Gepants are generally associated with nausea (1–2%) as the most common adverse event, with overall adverse event profiles comparable to placebo [10][11][13].

There are no known drug-drug interactions with anti-CGRP monoclonal antibodies due to their elimination via the reticuloendothelial system rather than hepatic metabolism. Gepants, however, are metabolized by CYP3A4 and are subject to interactions with strong CYP3A4 inhibitors and inducers. Ubrogepant is contraindicated with strong CYP3A4 inhibitors, while atogepant requires dose reduction [10][13].

The question of whether long-term CGRP blockade impairs wound healing — given the newly discovered role of CGRP in tissue repair [22] — remains an open area of investigation. Similarly, the implications for patients with peripheral neuropathy (who already have impaired CGRP signaling) merit further study.

March 2025 FDA Class-Wide Safety Labeling Update

In March 2025, the FDA updated the prescribing information for all CGRP monoclonal antibodies and gepants to include class-wide warnings regarding the potential for developing or worsening pre-existing hypertension and Raynaud's phenomenon. For erenumab specifically, constipation was also added to the labeling. Regarding Raynaud's phenomenon, post-marketing case reports identified symptom onset at a median of 71 days after dosing, with many cases involving serious outcomes including hospitalization and disability related to debilitating pain. In most cases, discontinuation of the CGRP antagonist led to symptom resolution. These labeling changes apply to all eight FDA-approved CGRP-targeting therapies (four monoclonal antibodies and four gepants) and reinforce the need for blood pressure monitoring and clinical vigilance for Raynaud's-like symptoms in patients receiving any anti-CGRP therapy.

8. Dosing of Approved Anti-CGRP Therapies

9. Pharmacokinetics

Endogenous CGRP Pharmacokinetics

Endogenous CGRP has remarkably rapid clearance kinetics, reflecting its role as a locally acting neuropeptide rather than a circulating hormone [4][28]:

• Plasma half-life: Approximately 6.9 minutes (range 5-10 minutes in human studies), making it one of the shortest-lived vasoactive peptides in circulation
• Clearance mechanism: Rapid enzymatic degradation by neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11) and other serum peptidases; receptor-mediated internalization of CGRP-receptor complexes; and hepatic/renal clearance
• Basal plasma levels: 25-50 pg/mL in healthy subjects (measured by radioimmunoassay in jugular venous blood)
• Ictal levels: During migraine attacks, jugular venous CGRP rises to 80-120 pg/mL or higher, representing a 2-3 fold increase from baseline (Goadsby and Edvinsson 1990) [5]
• Post-triptan levels: CGRP levels normalize following successful triptan treatment, confirming that elevated CGRP is associated with the active migraine state [5][14]

The short half-life of endogenous CGRP means that elevated levels during migraine reflect ongoing active release from trigeminal nerve terminals rather than impaired clearance.

Pharmacokinetics of Anti-CGRP Monoclonal Antibodies

The monoclonal antibodies targeting the CGRP pathway have dramatically different pharmacokinetics compared to endogenous CGRP, reflecting their large molecular size (approximately 150 kDa) and IgG structure:

| Parameter | Erenumab | Fremanezumab | Galcanezumab | Eptinezumab | |---|---|---|---|---| | Target | CGRP receptor (CLR/RAMP1) | CGRP ligand | CGRP ligand | CGRP ligand | | Route | SC | SC | SC | IV | | Half-life | ~28 days | ~31 days | ~27 days | ~27 days | | Tmax | 4-6 days | 5-7 days | 5-7 days | Immediate (IV) | | Bioavailability (SC) | ~82% | ~55-66% | ~60% | 100% (IV) | | Steady state | ~12 weeks | ~6 months (monthly) | ~12 weeks | ~6 months | | Elimination | Reticuloendothelial system (not hepatic CYP) | Reticuloendothelial system | Reticuloendothelial system | Reticuloendothelial system | | Drug interactions | None significant | None significant | None significant | None significant | | Washout period | ~16-20 weeks post-discontinuation | ~20-24 weeks | ~16-20 weeks | ~16-20 weeks |

The long half-lives (approximately 4 weeks) enable monthly or quarterly dosing but also mean that adverse effects, once established, persist for weeks after discontinuation. The Raffaelli et al. (2019) study showed that migraine frequency returned to baseline within 4-12 weeks after stopping erenumab or galcanezumab, corresponding to antibody washout kinetics [23].

Pharmacokinetics of Gepants (Small-Molecule CGRP Receptor Antagonists)

Gepants occupy a pharmacokinetic middle ground between the short-lived endogenous peptide and the long-acting antibodies:

| Parameter | Ubrogepant | Rimegepant | Atogepant | |---|---|---|---| | Molecular weight | ~484 Da | ~535 Da | ~604 Da | | Route | Oral | Oral (ODT) | Oral | | Half-life | ~5-7 hours | ~11 hours | ~11 hours | | Tmax | ~1.5 hours | ~1.5 hours | ~1-2 hours | | Oral bioavailability | ~6% | ~64% | Approximately 60% | | Metabolism | CYP3A4 | CYP3A4, CYP2C9 | CYP3A4 | | Drug interactions | Strong CYP3A4 inhibitors (contraindicated) | Moderate CYP3A4 interaction | CYP3A4 (dose adjust) | | Onset of action | ~1 hour | ~1 hour | N/A (preventive) |

The shorter half-lives of gepants translate to important clinical differences: less constipation (shorter duration of CGRP blockade in the gut), no need for washout before switching therapies, and the ability to use them intermittently for acute treatment [10][11][13].

10. Migraine Threshold and CGRP Levels

CGRP as a Migraine Biomarker

CGRP levels serve as both a pathophysiological mediator and a potential clinical biomarker for migraine [5][14][28]:

Interictal (between attacks) CGRP levels:

• Chronic migraine patients have elevated interictal CGRP levels (approximately 60-80 pg/mL) compared to episodic migraineurs (approximately 40-60 pg/mL) and healthy controls (approximately 25-50 pg/mL)
• Higher interictal CGRP levels are associated with higher migraine frequency and greater response to anti-CGRP therapy

Ictal (during attacks) CGRP levels:

• Jugular venous CGRP rises 2-3 fold during acute migraine attacks (Goadsby and Edvinsson 1990) [5]
• CGRP levels normalize with effective triptan treatment, confirming a causal relationship
• Intravenous CGRP infusion (1.5-2.0 micrograms/min for 20 minutes) triggers migraine-like attacks in approximately 57-75% of migraine patients but not in healthy controls, establishing a threshold sensitivity [14][28]

CGRP threshold concept: The observation that CGRP infusion triggers migraine only in susceptible individuals suggests a threshold model: migraine patients have a lower threshold for CGRP-mediated trigeminovascular activation, such that endogenous CGRP release (during stress, hormonal changes, or cortical spreading depression) exceeds this threshold and triggers an attack. Anti-CGRP therapies work by raising this effective threshold -- either by reducing available CGRP (ligand antibodies), blocking its receptor (erenumab, gepants), or both.

Dose-Response of Anti-CGRP Therapies

Erenumab dose-response (STRIVE trial) [6]:

• Placebo: -1.8 monthly migraine days (MMD)
• 70 mg: -3.2 MMD (50% responder rate: 43.3%)
• 140 mg: -3.7 MMD (50% responder rate: 50.0%)
• The 140 mg dose provides a modest additional benefit over 70 mg, suggesting partial dose-response saturation

Atogepant dose-response (ADVANCE trial) [13]:

• Placebo: -2.5 MMD
• 10 mg daily: -3.7 MMD
• 30 mg daily: -3.9 MMD
• 60 mg daily: -4.2 MMD
• Near-linear dose-response across the studied range

Galcanezumab dose-response (EVOLVE-1) [8]:

• Placebo: -2.8 MMD
• 120 mg: -4.7 MMD
• 240 mg: -4.6 MMD
• No additional benefit at the higher dose, suggesting a ceiling effect

11. Comparative Effectiveness

Anti-CGRP Therapies vs. Triptans for Acute Migraine

Triptans (5-HT1B/1D receptor agonists) remain the established standard for acute migraine treatment. Gepants represent a fundamentally different mechanism:

| Parameter | Triptans (sumatriptan 100 mg) | Ubrogepant (50-100 mg) | Rimegepant (75 mg) | |---|---|---|---| | Mechanism | 5-HT1B/1D agonism; vasoconstriction; inhibits CGRP release | CGRP receptor blockade (no vasoconstriction) | CGRP receptor blockade (no vasoconstriction) | | 2-hour pain freedom | ~28-32% | ~19-21% | ~20-21% | | 2-hour pain relief | ~60-65% | ~55-60% | ~55-60% | | NNT (pain freedom) | ~4-5 | ~11-12 | ~9 | | Cardiovascular contraindication | Yes (coronary artery disease, uncontrolled HTN, stroke history) | No | No | | Triptan sensation (chest tightness) | Yes (up to 5%) | No | No | | Medication overuse headache risk | Yes (with use on 10 or more days/month) | No evidence to date | No evidence to date | | Dual acute + preventive use | No | No | Yes (rimegepant only) | | Speed of onset | ~30-60 min (oral); ~15 min (SC sumatriptan) | ~60 min | ~60 min |

Key clinical distinction: Triptans remain more effective for acute pain freedom (NNT 4-5 vs. 9-12 for gepants) but carry cardiovascular contraindications that exclude approximately 10-15% of migraine patients. Gepants fill an important gap for patients with cardiovascular risk factors, triptan non-responders, and those at risk of medication overuse headache [10][11].

Anti-CGRP Therapies vs. NSAIDs for Acute Migraine

| Parameter | Ibuprofen (400 mg) | Naproxen sodium (500-550 mg) | Gepants (class) | |---|---|---|---| | 2-hour pain freedom | ~12-15% | ~10-14% | ~19-21% | | NNT (pain freedom) | ~7-10 | ~9-12 | ~9-12 | | GI adverse effects | Significant (gastric erosion, ulceration) | Significant | Minimal (nausea 1-2%) | | Cardiovascular risk | Increased with chronic use | Lowest CV risk among NSAIDs | No evidence of increased risk | | Renal effects | Nephrotoxic with chronic use | Nephrotoxic with chronic use | None documented | | Migraine-specific mechanism | No (general anti-inflammatory) | No (general anti-inflammatory) | Yes (CGRP pathway targeted) |

Anti-CGRP Monoclonal Antibody Class Comparison

| Feature | Erenumab (Aimovig) | Fremanezumab (Ajovy) | Galcanezumab (Emgality) | Eptinezumab (Vyepti) | |---|---|---|---|---| | Target | CGRP receptor | CGRP ligand | CGRP ligand | CGRP ligand | | Antibody type | Fully human IgG2 | Humanized IgG2-delta-a | Humanized IgG4 | Humanized IgG1 | | Route | SC (autoinjector) | SC (autoinjector/syringe) | SC (autoinjector/syringe) | IV infusion (~30 min) | | Dosing frequency | Monthly | Monthly or quarterly | Monthly (loading dose) | Quarterly (IV) | | 50% responder rate (episodic) | 43-50% | 44-48% | 47-62% | 50-56% | | Onset of efficacy | Week 1-4 | Week 1-4 | Week 1-4 | Day 1 (fastest onset) | | Cluster headache indication | No | No | Yes (only mAb approved) | No | | Constipation rate (real-world) | Highest (receptor blockade at all sites) | Moderate | Moderate | Moderate | | Injection site reactions | 3-6% | 17-45% (highest in class) | 8-18% | N/A (IV) | | Alopecia reports | Post-marketing signal | Less common | Less common | Less common | | Autoinjector convenience | Yes | Yes | Yes | Requires clinical setting |

Key differentiating factors:

• Erenumab is unique as the only receptor-targeted antibody; may have stronger constipation effects due to receptor blockade at all tissue sites
• Fremanezumab offers quarterly dosing convenience with a single 675 mg SC injection
• Galcanezumab is the only mAb approved for episodic cluster headache
• Eptinezumab has the fastest onset of action (day 1 efficacy) due to IV administration, making it suitable for patients needing rapid onset or who have failed SC options

12. Enhanced Safety Profile

Quantitative Safety Data Across Anti-CGRP Drug Classes

Monoclonal antibodies (pooled class data from pivotal trials):

• Injection site reactions: 3-45% depending on antibody and formulation (fremanezumab highest)
• Constipation: 1-3% in pivotal trials, but 30-50% or higher in real-world surveys [24]
• Serious adverse events: Rates comparable to placebo across all pivotal trials (1-3% in both groups)
• Treatment discontinuation due to AEs: 1-4% (comparable to placebo)
• Anaphylaxis/serious hypersensitivity: Reported rarely with eptinezumab and galcanezumab (less than 0.1%)
• Cardiovascular events: No increase in MACE in clinical trials or post-marketing surveillance through 5+ years [20][25]
• Alopecia: Post-marketing signal particularly with erenumab; mechanism unclear
• Hepatotoxicity: No signal (antibodies cleared by reticuloendothelial system, not liver)
• Immunogenicity: Anti-drug antibodies detected in 0-6% depending on antibody; generally non-neutralizing and without clinical impact

Gepants (pooled class data):

• Nausea: 1-4% (most common AE across the class)
• Fatigue: 1-3%
• Hepatotoxicity: None with current gepants (first-generation gepant olcegepant caused hepatic concerns, leading to reformulation of the entire class)
• Serious adverse events: Comparable to placebo in all pivotal trials
• Cardiovascular events: No signal (no vasoconstrictive properties; explicitly studied in patients with cardiovascular risk factors)
• Medication overuse headache: No evidence to date with rimegepant every-other-day or ubrogepant as-needed use
• Drug interactions: CYP3A4 interactions require attention (ubrogepant contraindicated with strong inhibitors; atogepant requires dose adjustment)

Cardiovascular Safety Assessment

The theoretical cardiovascular risk of blocking a potent endogenous vasodilator remains the most carefully monitored safety concern [20][25]:

Evidence of cardiovascular safety:

• No increase in MACE (major adverse cardiovascular events) across more than 25,000 patient-years of anti-CGRP mAb exposure in clinical trials and post-marketing data
• A dedicated cardiovascular safety study in older adults and adults with disability showed no increased risk of composite CVD events, hypertensive crisis, or peripheral revascularization [25]
• No clinically significant blood pressure increases documented with any anti-CGRP therapy

Ongoing monitoring concerns:

• Patients with established coronary artery disease, heart failure, and severe hypertension were largely excluded from pivotal trials
• The CGRP-mediated cardioprotective reserve during acute ischemic events (e.g., myocardial infarction) cannot be tested prospectively in clinical trials
• Theoretical concern that long-term CGRP blockade could impair the protective vasodilatory response during cardiac ischemia [20]

Gastrointestinal Safety

Constipation has emerged as the most impactful real-world side effect [24]:

• Clinical trial rates: 1-3% across mAb trials (may be underreported)
• Real-world surveys: 30-50% or higher, with some patients discontinuing therapy
• Mechanism: CGRP has motor-stimulating and prosecretory functions in the intestine; blockade reduces peristalsis and fluid secretion [24]
• Management: Dietary fiber, osmotic laxatives; switching from erenumab (receptor blockade) to ligand-targeting mAb may reduce severity
• Gepants: Lower constipation rates due to shorter duration of CGRP blockade

Wound Healing Considerations

The 2024 Nature study demonstrating CGRP's role in promoting tissue healing via immune cell modulation [22] raises a new theoretical concern: chronic CGRP blockade could potentially impair wound healing and tissue repair, particularly in patients with diabetes or peripheral neuropathy who already have compromised sensory innervation. No clinical data currently address this question, but it represents an important area for ongoing pharmacovigilance.

13. Related Peptides

See also: Substance P, Adrenomedullin, Amylin (IAPP), Vasopressin (ADH)

14. References

1. [1] Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. (1982). Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. DOI PubMed
2. [2] Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. (1985). Calcitonin gene-related peptide is a potent vasodilator. Nature. DOI PubMed
3. [3] Brain SD, Grant AD. (2004). Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiological Reviews. DOI PubMed
4. [4] Russell FA, King R, Smillie SJ, Kodji X, Brain SD. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological Reviews. DOI PubMed
5. [5] Goadsby PJ, Edvinsson L, Ekman R. (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology. DOI PubMed
6. [6] Goadsby PJ, Reuter U, Hallstrom Y, et al. (2017). A controlled trial of erenumab for episodic migraine (STRIVE). New England Journal of Medicine. DOI PubMed
7. [7] Silberstein SD, Dodick DW, Bigal ME, et al. (2017). Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine. DOI PubMed
8. [8] Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. (2018). Evaluation of galcanezumab for the prevention of episodic migraine (EVOLVE-1). JAMA Neurology. DOI PubMed
9. [9] Ashina M, Saper J, Cady R, et al. (2020). Eptinezumab in episodic migraine (PROMISE-1). Cephalalgia. DOI PubMed
10. [10] Dodick DW, Lipton RB, Ailani J, et al. (2019). Ubrogepant for the treatment of migraine (ACHIEVE I). New England Journal of Medicine. DOI PubMed
11. [11] Croop R, Goadsby PJ, Stock DA, et al. (2019). Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine. The Lancet. DOI PubMed
12. [12] Lipton RB, Croop R, Stock EG, et al. (2021). Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine prevention. The Lancet. DOI PubMed
13. [13] Ailani J, Lipton RB, Goadsby PJ, et al. (2021). Atogepant for the preventive treatment of migraine (ADVANCE). New England Journal of Medicine. DOI PubMed
14. [14] Edvinsson L, Haanes KA, Warfvinge K, Krause DN. (2018). CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nature Reviews Neurology. DOI PubMed
15. [15] Iyengar S, Ossipov MH, Johnson KW. (2017). The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. DOI PubMed
16. [16] Hay DL, Garelja ML, Poyner DR, Walker CS. (2018). Update on the pharmacology of calcitonin/CGRP family of peptides. British Journal of Pharmacology. DOI PubMed
17. [17] Eftekhari S, Salvatore CA, Caber S, et al. (2010). Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. DOI PubMed
18. [18] Iyengar S, Johnson KW, Ossipov MH, Aurora SK. (2019). CGRP and the trigeminal system in migraine. Headache. DOI PubMed
19. [19] Smillie SJ, Brain SD. (2011). Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides. DOI PubMed
20. [20] MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. (2016). Wiping out CGRP: potential cardiovascular risks. Trends in Pharmacological Sciences. DOI PubMed
21. [21] Bunce JV, Lundberg LM, Lundberg JM. (1993). Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. The Lancet. DOI PubMed
22. [22] Shao B, Bhatt D, et al. (2024). CGRP sensory neurons promote tissue healing via neutrophils and macrophages. Nature. DOI PubMed
23. [23] Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U. (2019). Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. The Journal of Headache and Pain. DOI PubMed
24. [24] Rubio-Beltran E, Chan KY, et al. (2022). Constipation caused by anti-CGRP migraine therapeutics explained by antagonism of CGRP's motor-stimulating and prosecretory function in the intestine. Frontiers in Physiology. DOI PubMed
25. [25] Deen M, Correnti E, Kamm K, et al. (2017). Blocking CGRP in migraine patients — a review of pros and cons. The Journal of Headache and Pain. DOI PubMed
26. [26] Birk S, Sitarz JT, Petersen KA, et al. (2012). The role of calcitonin gene-related peptide in cerebral vasospasm and subarachnoid hemorrhage. Frontiers in Neurology. DOI PubMed
27. [27] Hay DL, Walker CS. (2017). CGRP and its receptors. Headache. DOI PubMed
28. [28] Russo AF. (2015). Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual Review of Pharmacology and Toxicology. DOI PubMed